Author

Anne Jokilammi

Åbo Akademi UniversityORCID 0000-0002-1675-5737Unclaimed ORCID profile · follow to get notified of new preprints

Biology Disciplines

Click to filter author papers

Signature Assays, Organisms & Methods

Click to filter · or open tag

Research Focus:cell signaling & trafficking· 2 Approach:experimental assay· 2 Research Focus:cancer & tumor microenvironment· 1 Research Focus:drug response / drug discovery· 1 Research Focus:host-pathogen & immune response· 1 Organism:human· 1 Assay:proteomics· 1 Organism:zebrafish· 1

Frequent Co-Authors

Klaus EleniusiD· 2 shared Aura Tuohisto-Kokko· 1 shared Cecilia SahlgreniD· 1 shared Deepankar ChakrobortyiD· 1 shared Ilkka PaateroiD· 1 shared Iman Farahani· 1 shared Iman Khani FarahaniiD· 1 shared Johanna ÖrlingiD· 1 shared

Activity by Year

2024-2025 · peak 1/yr

Co-Author Collaboration Network

10 top collaborators · 25 mutual co-author links

Click any collaborator node to inspect or filter shared papers

Focal author (center)Selected co-authorORCID co-authorUnlinked name

Curved chords = mutual co-authorship

2 shared papersCancer Biology

Klaus EleniusORCID

Mutual co-authors in cluster

Author profile →

2 papers

Recent·Most cited

Recurrent cancer-associated ERBB4 mutations are transforming and confer resistance to targeted therapies

Veera K. Ojala, Sini Ahonen, Sara Peltola, Aura Tuohisto-Kokko, Olaya Esparta, Peppi Suominen, Anne Jokilammi, Iman Khani Farahani, Deepankar Chakroborty, Nikol Dibus, Steffen Boettcher, Tomi T. Airenne, M. S. Johnson, Lisa D. Eli, Klaus Elenius, Kari J. Kurppa

This study identifies recurrent ERBB4 mutations with oncogenic potential and resistance to targeted therapies, suggesting clinical implications for treatment strategies.

Molecular Oncology · Dec 23, 2025Peer-reviewedCancer Biology

Phosphoproteomic analysis reveals the diversity of signaling behind ErbB inhibitor-induced phenotypes

Katri Vaparanta, Zejia Song, Iman Farahani, Anne Jokilammi, Johannes Merilahti, Johanna Örling, Noora Virtanen, Pekka Haapaniemi, Cecilia Sahlgren, Klaus Elenius, Ilkka Paatero

This study uses phosphoproteomic analysis in zebrafish to show that ErbB inhibitors affect multiple signaling pathways, leading to similar physiological phenotypes.

bioRxiv · Mar 12, 2024Cell Biology